Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Brown Miller Wealth Management LLC

Brown Miller Wealth Management LLC boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 123.4% during the 1st quarter, Holdings Channel.com reports. The firm owned 6,939 shares of the biopharmaceutical company’s stock after purchasing an additional 3,833 shares during the quarter. Brown Miller Wealth Management LLC’s holdings in Gilead Sciences were worth $778,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of Gilead Sciences during the 4th quarter worth about $1,789,254,000. FMR LLC boosted its stake in shares of Gilead Sciences by 21.6% during the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company’s stock worth $3,724,306,000 after acquiring an additional 7,157,113 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Gilead Sciences by 13,891.1% during the 1st quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company’s stock worth $285,761,000 after acquiring an additional 2,532,070 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Gilead Sciences by 19.7% during the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company’s stock worth $1,377,707,000 after acquiring an additional 2,458,954 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Gilead Sciences during the 4th quarter worth about $207,340,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $99.82, for a total transaction of $249,550.00. Following the completion of the sale, the chief financial officer now owns 165,674 shares in the company, valued at $16,537,578.68. This trade represents a 1.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the sale, the insider now owns 121,152 shares of the company’s stock, valued at $13,026,263.04. This represents a 18.77% decrease in their position. The disclosure for this sale can be found here. Insiders sold 43,000 shares of company stock worth $4,630,310 in the last 90 days. Insiders own 0.27% of the company’s stock.

Gilead Sciences Trading Down 1.8%

GILD opened at $109.98 on Monday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The company’s 50 day simple moving average is $105.67 and its two-hundred day simple moving average is $102.33. Gilead Sciences, Inc. has a 1-year low of $62.69 and a 1-year high of $119.96. The firm has a market capitalization of $136.81 billion, a price-to-earnings ratio of 297.24, a price-to-earnings-growth ratio of 0.71 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The business’s revenue was down .3% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.32) EPS. Analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be issued a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.87%. Gilead Sciences’s dividend payout ratio is currently 66.53%.

Wall Street Analysts Forecast Growth

GILD has been the topic of several recent analyst reports. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $125.00 target price on the stock. Wells Fargo & Company raised their price target on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. JPMorgan Chase & Co. raised their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a research note on Thursday, March 27th. Finally, Oppenheimer decreased their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, April 25th. Nine research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $110.55.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.